title: [Immunohistochemical and clinicopathological study of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyl transferase expression in oral cancer patients responding to UFT].
abstract: Thymidylate synthase(TS), dihydropyrimidine dehydrogenase(DPD), and orotate phosphoribosyl transferase(OPRT)are initial key enzymes in the 5-fluorouracil(5-FU)metabolic pathway. In this study, we investigated clinicopathological and immunohistochemical expressions of TS, DPD, and OPRT in oral cancer patients who showed a complete response(CR)to UFT. We also evaluated patients showing a partial response(PR)and stable disease(SD)following UFT. The numbers of CR, PR, and SD cases were 3, 5, and 10, respectively. Pathologically, all CR and PR cases were the well-differentiated type, and 5 out of 10 SD cases were of the moderately or poorly-differentiated type. Three out of the 5 cases of moderately or poorlydifferentiated type were DPD-negative. Most cases of CR and PR were DPD-positive. OPRT expression showed no difference with the UFT response. We suggest that UFT affects high DPD patients with the well-differentiated type, but may not influence low DPD patients with the moderately or poorly-differentiated type.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Unit of Translational Medicine, Course of Medical and Dental Sciences, Nagasaki University Graduate School of Biomedical Sciences.
authors.forename: Goro
authors.initials: G
authors.lastname: Kawasaki
authors.forename: Izumi
authors.initials: I
authors.lastname: Yoshitomi
authors.forename: Souichi
authors.initials: S
authors.lastname: Yanamoto
authors.forename: Shin-Ichi
authors.initials: S
authors.lastname: Yamada
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Kawano
authors.forename: Akio
authors.initials: A
authors.lastname: Mizuno
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002454:Cell Differentiation; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D009962:Orotate Phosphoribosyltransferase / Q000378:metabolism*; D005641:Tegafur / Q000627:therapeutic use; D013940:Thymidylate Synthase / Q000378:metabolism*; D014498:Uracil / Q000627:therapeutic use
chemical_list: D005641:Tegafur; D014498:Uracil; D042943:Dihydrouracil Dehydrogenase (NADP); D013940:Thymidylate Synthase; D009962:Orotate Phosphoribosyltransferase